Off-the-Shelf, ‘TURBOCHARGED’ γδ1/3 CAR-T Cells, Designed to Treat Solid Tumors.
γδ1/3 T Cells provide an ideal solution for solid tumors and are turbocharged by Cellepus’ precision engineering.
Evolved to naturally home to solid tumors
Delivered Off-the-Shelf
Proven safe in humans
Form durable memory response
Comprehensively Engineered
Scalable manufacturing using cord blood
Patented novel “Zeta-less” signaling architecture to enhance tumor killing
Highly tumor-specific antigen targets characterized by Cellepus
Genetically engineered to avoid exhaustion and maintain stemness
The Next Leap in T Cell Therapy
-
γδ1/3 cells have an innate ability to hone to and penetrate solid tumors, and have a significant advantage in killing tumor cells when compared to circulating γδ2 cells.
-
Cellepus has created novel and precision-guided γδ1/3 CAR T cells against solid tumors using a proprietary “Zeta-less” CAR signaling architecture that resists exhaustion intrinsic to traditional CD28/41BB frameworks.
-
Cellepus has identified novel and precision-guided tumor antigen targets with low off-tumor effects using the following approaches.
• A multi-omics approach focused on SCLC from patients
• Identifying cancer targeting mAbs from ovarian cancer patients
-
Altogether, our “turbocharged” allogeneic γδ1/3 CAR-Ts is a highly differentiated and state-of-the-art cell therapy therapeutic platform for solid tumor impasse.
Scientific Founders
-
Jose Conejo-Garcia, MD PhD
CO-FOUNDER, ACTING CSO
Joined the ovarian cancer team at the UPenn in 2001 that identified for the first time the role of T cell responses in the outcome of ovarian cancer patients. Was leader of the Tumor Microenvironment and Metastasis Program at The Wistar Institute. In 2016 made Chair of the Department of Immunology at H. Lee Moffitt Cancer Research Institute. In 2023 he was recruited as a Duke Science and Technology Scholar.
-
Scott Antonia, MD PhD
CO-FOUNDER
Director, Center for Cancer Immunotherapy at Duke Cancer Institute, and Professor of Medicine at Duke University, where he is a lung cancer physician where he leads Center for Cancer Immunotherapy. Prior to joining Duke University, he was at Moffitt Cancer Center developing immunotherapies to fight lung cancer, including one that in June 2019 changed the standard of care for stage III non-small-cell lung cancer.